TY - JOUR T1 - Outcome after heart–lung or lung transplantation in patients with Eisenmenger syndrome JF - Heart JO - Heart SP - 127 LP - 132 DO - 10.1136/heartjnl-2019-315345 VL - 106 IS - 2 AU - Cristel S Hjortshøj AU - Thomas Gilljam AU - Göran Dellgren AU - Markku O Pentikäinen AU - Thomas Möller AU - Annette Schophuus Jensen AU - Maila Turanlahti AU - Ulf Thilén AU - Finn Gustafsson AU - Lars Søndergaard Y1 - 2020/01/01 UR - http://heart.bmj.com/content/106/2/127.abstract N2 - Objective The optimal timing for transplantation is unclear in patients with Eisenmenger syndrome (ES). We investigated post-transplantation survival and transplantation-specific morbidity after heart–lung transplantation (HLTx) or lung transplantation (LTx) in a cohort of Nordic patients with ES to aid decision-making for scheduling transplantation.Methods We performed a retrospective, descriptive, population-based study of patients with ES who underwent transplantation from 1985 to 2012.Results Among 714 patients with ES in the Nordic region, 63 (9%) underwent transplantation. The median age at transplantation was 31.9 (IQR 21.1–42.3) years. Within 30 days after transplantation, seven patients (11%) died. The median survival was 12.0 (95% CI 7.6 to 16.4) years and the overall 1-year, 5-year, 10-year and 15-year survival rates were 84.1%, 69.7%, 55.8% and 40.6%, respectively. For patients alive 1 year post-transplantation, the median conditional survival was 14.8 years (95% CI 8.0 to 21.8), with 5-year, 10-year and 15-year survival rates of 83.3%, 67.2% and 50.0%, respectively. There was no difference in median survival after HLTx (n=57) and LTx (n=6) (14.9 vs 10.6 years, p=0.718). Median cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis/kidney transplantation-free survival rates were 11.2 (95% CI 7.8 to 14.6), 6.9 (95% CI 2.6 to 11.1) and 11.2 (95% CI 8.8 to 13.7) years, respectively. The leading causes of death after the perioperative period were infection (36.7%), bronchiolitis obliterans syndrome (23.3%) and heart failure (13.3%).Conclusions This study shows that satisfactory post-transplantation survival, comparable with contemporary HTx and LTx data, without severe comorbidities such as cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis, is achievable in patients with ES, with a conditional survival of nearly 15 years. ER -